• Small Molecules
    • Biologics
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery
      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

    • Industries
    • Emerging Biopharma
      • Emerging Biopharma

        Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.

    • Dedicated Centers
      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

    • Center for Advanced Protein Studies (CAPS)
      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

  • Careers

Forging partnerships for success with strategic outsourcing

Forging partnerships for success with strategic outsourcing

In today’s rapidly evolving global economy, businesses are under constant pressure to innovate, scale, and stay competitive. Traditional cost-cutting measures are no longer sufficient. Instead, strategic outsourcing has emerged as a powerful lever for growth—especially in the life sciences sector.

This session will delve into:

  • The evolution of outsourcing from a cost-saving tactic to a strategic growth enabler
  • Key trends driving the expansion of the biologics CDMO market
  • How companies are building meaningful partnerships to streamline operations and foster innovation

Whether you’re a biotech startup or an established pharmaceutical company, this webinar will provide valuable insights into leveraging outsourcing as a strategic advantage in a competitive landscape.

Join us for an insightful webinar exploring the rise of strategic outsourcing and its transformative impact on the biologics industry. With the Biologics CDMO market projected to grow from $10.59 billion in 2024 to $16.36 billion by 2030, organizations—particularly virtual and lean enterprises—are increasingly turning to Contract Development and Manufacturing Organizations (CDMOs) and Contract Research Organizations (CROs) to access specialized expertise, accelerate timelines, and reduce infrastructure costs.

Resources

How Sygnene delivered more than 90% purity pDNA for a global biotech using a proprietary platform process
Regulatory role of Biophysics in Biologics CMC
Intensified Biomanufacturing
Achieving Biologics manufacturing milestones using a systemic approach to Technology Transfer

To view or email, Please share your details view

Your browser does not support this function.

To download, Please share your details

To view or email, Please share your details view

To download, Please share your details